PANews reported on October 7 that according to Globenewswire, MAIA Biotechnology, listed on NYSE American under the New York Stock Exchange, announced the official launch of its crypto treasury strategy. At the same time, its board of directors has approved investing 90% of the company's liquid assets in leading cryptocurrencies. The initial investment will purchase BTC, ETH and USDC. It is reported that the company will also establish a digital asset advisory committee to provide support for related purchase transactions.
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact
[email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.